Magenta Therapeutics Stock Price. Everything You Need To Know About The Magenta Therapeutics Stock!
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Magenta Therapeutics Stock Price. Everything You Need To Know About The Magenta Therapeutics Stock! performance
- Employees 67
- Company HQ Cambridge
- Website https://www.magentatx.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
If you’re a retail investor from Malaysia, Thailand, Indonesia, or Vietnam, looking to expand your investment portfolio in the healthcare sector, Magenta Therapeutics is a stock worth considering. As a content marketing expert at Zorion, I am here to provide you with insights and recommendations on how to invest in this promising company. Magenta Therapeutics is a biotechnology company that focuses on developing innovative therapies for patients with autoimmune diseases, blood cancers, and genetic disorders. With a strong pipeline of potential treatments and a track record of success, investing in Magenta Therapeutics can be a lucrative opportunity. To learn how you can invest in this stock and seize the potential profits it offers, explore the resources and educational materials that Zorion provides to retail investors like yourself.
